Health Economic Modelling of Antimicrobial resistance in Australia - HEMAA

The Health Economic Modelling of Antimicrobial resistance in Australia (HEMAA) project aims to determine the health and economic burden of common resistant organisms which have shown to be of importance in Australia. These E.coli ,K.pneumoniae, P. aeruginosa, E. faecium and S.aureus. The HEMAA team have developed an economic model to provide a robust estimate the burden of antimicrobial resistance in the tertiary healthcare sector in Australia.  The model is used to estimate: total number of infections; the proportion resistant; antimicrobial management ; attributable morbidity and mortality and overall excess costs of resistant infections.

Prevalence of key organisms are sourced from Australian-based data sets and where data are missing, the model is supplemented with published international studies. This is the first of such studies in Australia and is timely given the imminent release of the first National AMR Strategy (2015-2019) and the work currently underway by the Australian Commission on Safety and Quality in Health Care


Relevant publications:

Wozniak TM, Paterson D, Halton K (2017) Review of the epidemiological data regarding antimicrobial resistance in Gram negative bacteria in Australia. Infection, Disease & Health

Wozniak TM, Graves N, Barnett AG. (2017)  How much do superbugs cost Australian hospitals? An evidence-based open-access tool. 

Wozniak TM (2017) Clinical management of drug-resistant bacteria in Australian hospitals: an online survey of doctors' opinions. Infection, Disease & Health (forthcoming)


Dr Kate Halton
Dr Teresa Wozniak